Guidance for Treating the Older Adults with Colorectal Cancer

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

Surveillance E, and End Results (SEER) Program. Cancer Stat Facts: Colorectal Cancer. https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 9/10/2022.

Siegel RL, Miller KD, Goding Sauer A et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70(3):145–164. https://doi.org/10.3322/caac.21601.

Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.

Vincent G, Velkoff V. The next four decades: the older population in the United States - 2010 to 2050: Population estimates and projections. . U.S. Census Bureau, May 2010.

U.S. Census Bureau. 2012-2016 American Community Survey 5-Year Estimates. https://www.census.gov/programs-surveys/acs/technical-documentation/table-and-geography-changes/2016/5-year.html. Accessed 9/9/2022.

Desantis CE, Miller KD, Dale W et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin 2019;69(6):452–467. https://doi.org/10.3322/caac.21577.

SEER Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 9/10/2022.

Walter V, Boakye D, Weberpals J, et al. Decreasing use of chemotherapy in older patients with stage III colon cancer irrespective of comorbidities. J Nat Compr Cancer Netw. 2019;17(9):1089–99. https://doi.org/10.6004/jnccn.2019.7287.

Article  CAS  Google Scholar 

Chang HJ, Lee KW, Kim JH, et al. Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol. 2012;23(4):911–8. https://doi.org/10.1093/annonc/mdr329.

Article  CAS  PubMed  Google Scholar 

Antonio M, Carmona-Bayonas A, Saldana J et al. Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study. Clin Colorectal Cancer 2018;17(1):e59-e68. https://doi.org/10.1016/j.clcc.2017.09.003. Well-designed elderly-specific trial with a good review of geriatric assessment.

Lund CM, Vistisen KK, Olsen AP, et al. The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO). Br J Cancer. 2021;124(12):1949–58. https://doi.org/10.1038/s41416-021-01367-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Francois E, Pernot M, Ronchin P et al. NACRE: A randomized study comparing short course radiotherapy with radiochemotherapy for locally advanced rectal cancers in the elderly—Preliminary results. J Clin Oncol 2021;39(3_suppl):4–4. https://doi.org/10.1200/JCO.2021.39.3_suppl.4. Elderly-specific rectal cancer trial.

Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749–59. https://doi.org/10.1016/s0140-6736(11)60399-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Ann Oncol. 2016;27(1):121–7. https://doi.org/10.1093/annonc/mdv491.

Article  CAS  PubMed  Google Scholar 

Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85. https://doi.org/10.1016/S1470-2045(13)70154-2.

Article  CAS  PubMed  Google Scholar 

Hamaguchi T, Takashima A, Mizusawa J et al. A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT). J Clin Oncol 2022;40(4_suppl):10–10. https://doi.org/10.1200/JCO.2022.40.4_suppl.010.

Lonardi S, Schirripa M, Buggin F et al. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study. J Clin Oncol 2020;38(15_suppl):4002–4002. https://doi.org/10.1200/JCO.2020.38.15_suppl.4002.

Petrioli R, Chirra M, Messuti L, et al. Efficacy and safety of regorafenib with 2/1 schedule for patients ≥ 75 years with metastatic colorectal cancer (mCRC) after failure of 2 lines of chemotherapy. Clin Colorec Cancer. 2018;17(4):307–12. https://doi.org/10.1016/j.clcc.2018.02.005.

Article  Google Scholar 

Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346(14):1061–6. https://doi.org/10.1056/NEJMsa012528.

Article  PubMed  Google Scholar 

Paillaud E, Caillet P, Laurent M et al. Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment. Clin Interven Aging. 2014:1645. https://doi.org/10.2147/cia.s57849.

Chaibi P, Magne N, Breton S, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol. 2011;79(3):302–7. https://doi.org/10.1016/j.critrevonc.2010.08.004.

Article  PubMed  Google Scholar 

Kalsi T, Babic-Illman G, Ross PJ, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112(9):1435–44. https://doi.org/10.1038/bjc.2015.120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li D, Sun CL, Kim H et al. Geriatric Assessment-Driven Intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol 2021;7(11):e214158. https://doi.org/10.1001/jamaoncol.2021.4158. Trial demonstrating the feasibility of geriatric assessment-guided therapy and subsequently improved patient outcomes.

Mohile SG, Mohamed MR, Xu H et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 2021;398(10314):1894–1904. https://doi.org/10.1016/S0140-6736(21)01789-X. Trial demonstrating the feasibility of geriatric assessment-guided therapy and subsequently improved patient outcomes.

Kalsi T, Babic-Illman G, Ross PJ, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015;112(9):1435–44. https://doi.org/10.1038/bjc.2015.120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dotan E, Walter LC, Browner IS et al. NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. J Nat Compr Cancer Netw 2021;19(9):1006–1019. https://doi.org/10.6004/jnccn.2021.0043.

Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–47. https://doi.org/10.1200/jco.2018.78.8687.

Article  PubMed  PubMed Central  Google Scholar 

Caillet P, Laurent M, Bastuji-Garin S, et al. Optimal management of elderly cancer patients: usefulness of the comprehensive geriatric assessment. Clin Interv Aging. 2014;9:1645–60. https://doi.org/10.2147/CIA.S57849.

Article  PubMed  PubMed Central  Google Scholar 

Basso U, Falci C, Brunello A et al. Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP). J Clin Oncol 2011;29(15_suppl):9065–9065. https://doi.org/10.1200/jco.2011.29.15_suppl.9065.

Caplan GA, Williams AJ, Daly B, Abraham K. A randomized, controlled trial of comprehensive geriatric assessment and multidisciplinary intervention after discharge of elderly from the emergency department–the DEED II study. J Am Geriatr Soc. 2004;52(9):1417–23. https://doi.org/10.1111/j.1532-5415.2004.52401.x.

Article  PubMed  Google Scholar 

Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017;9:CD006211. https://doi.org/10.1002/14651858.CD006211.pub3.

Frese T, Deutsch T, Keyser M, Sandholzer H. In-home preventive comprehensive geriatric assessment (CGA) reduces mortality–a randomized controlled trial. Arch Gerontol Geriatr. 2012;55(3):639–44. https://doi.org/10.1016/j.archger.2012.06.012.

Article  PubMed  Google Scholar 

Mohile SG, Velarde C, Hurria A, et al. Geriatric assessment-guided care processes for older adults: a delphi consensus of geriatric oncology experts. J Natl Compr Canc Netw. 2015;13(9):1120–30. https://doi.org/10.6004/jnccn.2015.0137.

Article  PubMed  PubMed Central  Google Scholar 

Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65. https://doi.org/10.1200/JCO.2011.34.7625.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31. https://doi.org/10.1200/JCO.2007.10.6559.

Article  PubMed  Google Scholar 

Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005. https://doi.org/10.1002/cncr.21422.

Article  PubMed  Google Scholar 

Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290–6. https://doi.org/10.1200/JCO.2010.30.6985.

Article  PubMed  PubMed Central  Google Scholar 

Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–9. https://doi.org/10.1046/j.1532-5415.2001.49281.x.

Article  CAS  PubMed  Google Scholar 

Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–72. https://doi.org/10.1093/annonc/mdr587.

Article  CAS  PubMed  Google Scholar 

Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34(20):2366–71. https://doi.org/10.1200/jco.2015.65.4327.

Article  PubMed  PubMed Central  Google Scholar 

Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86. https://doi.org/10.1002/cncr.26646.

Article  PubMed  Google Scholar 

Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–37. https://doi.org/10.1634/theoncologist.5-3-224.

Article  CAS  PubMed  Google Scholar 

Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345(8955):939–44. https://www.ncbi.nlm.nih.gov/pubmed/7715291. Accessed 9/10/2022.

O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16(1):295–300. https://doi.org/10.1200/JCO.1998.16.1.295.

Article  CAS  PubMed  Google Scholar 

Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17(5):1356–63. https://www.ncbi.nlm.nih.gov/pubmed/10334519. Accessed 9/10/2022.

Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Eng J Med. 2001;345(15):1091–7. https://doi.org/10.1056/nejmoa010957.

Article  CAS  Google Scholar 

André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Eng J Med. 2004;350(23):2343–51. https://doi.org/10.1056/nejmoa032709.

Article  Google Scholar 

André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16. https://doi.org/10.1200/jco.2008.20.6771.

Article  PubMed  Google Scholar 

Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant Tre. J Clin Oncol. 2012;30(27):3353–60. https://doi.org/10.1200/jco.2012.42.5645.

Article  CAS  PubMed 

留言 (0)

沒有登入
gif